From proteins to people: an open toolkit to accelerate Huntington's disease research
Poster for SAGE Assembly 2019
Summary: Huntington’s disease research has been hampered by a paucity of openly available biochemical tools to facilitate research into this devastating disease and help develop new therapeutics. This project aimed to generate resources for the Huntington’s disease research community, available without restriction, with the hope of accelerating research of the huntingtin protein which functions aberrantly in patients with this disease.
Dr. Harding is the recipient of the Huntington's Disease Society of America Berman Topper Career Development Fellowship which funds and supports this research, in addition to generous funding from the CHDI Foundation and the Huntington Society of Canada. The SGC is a registered charity (number 1097737) that receives funds from AbbVie, Bayer Pharma AG, Boehringer Ingelheim, Canada Foundation for Innovation, Eshelman Institute for Innovation, Genome Canada through Ontario Genomics Institute [OGI-055], Innovative Medicines Initiative (EU/EFPIA) [ULTRA-DD grant no. 115766], Janssen, Merck KGaA, Darmstadt, Germany, MSD, Novartis Pharma AG, Ontario Ministry of Research, Innovation and Science (MRIS), Pfizer, São Paulo Research Foundation-FAPESP, Takeda, and Wellcome.